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Abstract
Background:  The present study aimed at investigating in healthy volunteers the effects of diazepam and
clonazepam on beta-cell function, insulin sensitivity and glucose effectiveness based on the frequently sampled
intravenous (0.5 gkg-1) glucose tolerance test with minimal-model analysis.
Methods: The study was designed as a double-blind, placebo-controlled, cross-over clinical trial. Diazepam (10
mg) and clonazepam (1 mg) were infused during 30 min to 15 male subjects with a mean age of 22 years (range:
20–29), after informed consent was given. Benzodiazepines were assayed by capillary gas chromatography with
electron capture, insulin by radioimmunoassay and glucose by the enzymatic glucose oxidase method.
Results: Both benzodiazepines induced significant psychotropic effects. The acute insulin responses (AIR) were
significantly and negatively correlated with the clonazepam plasma concentrations (r = -0.609, P < 0.05, n = 14).
However, the mean AIR was not significantly different between the benzodiazepine-treated subjects and the
controls. In addition, the parameters of glucose assimilation were significantly decreased as compared with
placebo in the subgroup of 7 subjects with plasma clonazepam concentrations higher than 6.0 ng ml-1 (median and
lower limit of effective therapeutic concentrations): 1.37 ± 0.3 versus 2.84 ± 0.60 × 10-2min-1 (P = 0.028) for the
coefficient of glucose tolerance (Kg), 2.18 ± 0.29 versus 3.71 ± 0.89 × 10-4µUml-1min-1 (P = 0.018) for insulin
sensitivity (Si) and 1.80 ± 0.39 versus 3.59 ± 0.71 × 10-2min-1 (P = 0.028) for glucose effectiveness at basal insulin
(Sg). These parameters were not significantly modified when diazepam was administered; plasma levels of this drug
however, were below the effective therapeutic concentrations (300 ng ml-1) from min 15 after the end of the
perfusion.
Conclusion: The present results suggest that a benzodiazepine, in particular clonazepam, may alter insulin
secretion and insulin sensitivity after a single administration in healthy volunteers.
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Background
Benzodiazepine drugs are widely prescribed, mainly for
their anxiolytic and sedative properties. In addition to
these psychotropic actions, different metabolic effects
have also been reported but few clinical trials on that topic
are available.
A trend to increased glycemia without significant modifi-
cation of insulinemia was shown after a single dose
administration of diazepam in healthy volunteers [1].
Aggravation of hyperglycemia has been reported during
benzodiazepine treatment in diabetic patients [2]. In
patients treated with the imidazopyridine compound
alpidem, which binds benzodiazepine receptors [3], we
reported an alteration of glucose tolerance after one week
administration [4]. Studies in vitro have shown that some
benzodiazepines could affect insulin secretion differently
according to the experimental model [5,6].
Weight gain, which is often related to insulin resistance,
has also been claimed to occur in some patients treated
with benzodiazepines. Different benzodiazepines have
different effects on body weight gain in rats, suggesting
that different subtypes of benzodiazepine receptors are
involved [7].
In order to further explore the potential effects of benzo-
diazepines on beta-cell function and insulin sensitivity,
we performed in healthy volunteers the frequently sam-
pled intravenous glucose tolerance test with minimal-
model analysis according to Bergman et al. [8]. The single-
dose effects of two benzodiazepines, diazepam and clon-
azepam, with different affinity and selectivity for central
and peripheral receptors were investigated.
Methods
Fifteen healthy male volunteers, aged 20–29 years (mean
22.5 years), were included in this study. They underwent
a full medical examination with electrocardiogram and
standard biological screening before entry into the study.
All subjects were in good physical condition and of nor-
mal weight (mean: 68.6 kg; range: 55–81) and body mass
index (mean: 22.3 kg/m2; range: 20.1–25.0). They had no
previous history of significant disease and satisfied the
inclusion/exclusion criteria. All volunteers gave written
consent to participate after being informed of the aim of
the research, its experimental protocol and potential risks.
The study was approved by the institutional Ethics Com-
mittee of Montpellier and has been conducted in accord-
ance with the Helsinki declaration and the European
guideline for « Good Clinical Practice ».
The study was designed as a double-blind, three-way pla-
cebo-controlled cross-over investigation of diazepam, a
central and peripheral benzodiazepine receptor ligand
[9], clonazepam, a selective central receptor ligand [9],
and placebo. Subjects were randomly assigned to one of
the three treatment groups to control for potential order
effect. The three treatments were single intravenous doses
of diazepam (10 mg), clonazepam (1 mg) or placebo. The
three treatment administrations were separated by a 7-day
washout period.
In the morning of each test-day, subjects were admitted to
the Clinical Investigation Center, in fasting conditions for
at least 12 hours, namely from the evening before. The
subjects remained in the supine position and a venous
catheter was inserted in each forearm, one for the admin-
istration of the drugs and glucose, the other for blood
sampling. The drugs in 125 mL saline solution or the
saline solution alone (placebo) were administered during
30 min (between minutes -45 and -15). The treatments
were prepared by the research nurse according to the ran-
domization form. Fifteen minutes after the end of the per-
fusion, the frequently sampled intravenous glucose
tolerance test (FSIVGTT) was started, with a glucose load
of 0.5 g/kg in 3 min and a bolus of 0.03 U/kg insulin just
before minute 20. Blood samples were taken at times -45,
-15 and 0, then at 1, 3, 4, 6, 8, 10, 15, 19, 20, 22, 24, 30,
41, 70, 90 and 180 minutes after glucose injection for the
measurement of plasma glucose and serum insulin con-
centrations. Additional samples were taken at times -45, -
15, 0, then at 15, 30, 60, 120 and 180 minutes after glu-
cose injection for the measurement of plasma diazepam,
N-desmethyldiazepam, clonazepam and cortisol.
Furthermore, the subjects' mood and feelings were self-
rated before (time -45 min) and after the infusion (time -
15 min), and then at times 70 and 180 minutes, using the
49-item questionnaire from the Addiction Research
Center Inventory (ARCI) and the Norris series of 16 bipo-
lar visual analogue scales (VAS). At the end of the test day,
subjects were discharged after a last clinical evaluation.
After immediate centrifugation of the blood samples
(1500 g, 10 min), plasma or serum was separated and fro-
zen at -20°C. Plasma glucose levels were assayed by the
glucose oxidase method derived from Trinder [10]. Serum
insulin and plasma cortisol were measured by
radioimmunoassay using the marketed immunoradio-
metric kit INSIK-5 purchased from DiaSorin (Saluggia,
Italy). Diazepam, N-desmethyldiazepam and clonazepam
were assayed by a capillary gas chromatography technique
with electron capture, adapted from a previously pub-
lished method [11]. Briefly, benzodiazepines were
extracted from plasma at pH = 9.0 by ethyl ether. GLC
analysis was performed on a HP-5 (crosslinked 5 % PH
ME siloxane) 30 m × 0.32 mm × 0.25 µm capillary col-
umn (Agilent) at an oven temperature from 170 to 250°C
(2°C/min). The intra and inter-assay variability rangedBMC Clinical Pharmacology 2004, 4 http://www.biomedcentral.com/1472-6904/4/3
Page 3 of 10
(page number not for citation purposes)
from 4.7 % to 9.9 % for clonazepam, 2.7 % to 7.4 % for
diazepam and 5.4 % to 9.7 % for N-desmethyldiazepam
for three quality control concentrations.
Acute insulin response (AIR) was used as an index of the
first-phase insulin secretion and was calculated as the
mean of the serum insulin concentrations at times 1, 3, 4,
6, 8 and 10 minutes.
The least-square slope of the log of the absolute glucose
concentration between 4 and 19 minutes after the glucose
bolus was used as an index of glucose tolerance (Kg).
Minimal-model analysis of the FSIVGTT was performed
according to the method previously reported by Bergman
et al. [8] and Yang et al. [12], using the software TISPAG
from the Department of Clinical Physiology, Lapeyronie
University Hospital, (Montpellier, France), which uses a
nonlinear least-square estimation [13]. This program pro-
duced the values for insulin sensitivity (Si) and glucose
effectiveness (Sg). Si and Sg are calculated from the equa-
tions dG(t)/dt = -[p1 + X(t)]G(t) + p1Gb, G(0) = Go,
dX(t)/dt = -p2X(t) + p3 [I(t) - Ib], and X(0) = 0, where G(t)
and I(t) are plasma glucose and insulin concentrations,
X(t) is the insulin in a compartment remote from plasma
(insulin action), and p1 to p3 are model parameters. Go
is the glucose concentration that would be obtained
immediately after injection if there was instantaneous
mixing in the extracellular fluid compartment. Gb and Ib
are basal values of glucose and insulin. Parameter p1 rep-
resents Sg, i.e. the fractional disappearance rate of glucose
independent of any insulin response, and p3 and p2
determine the kinetics of insulin transport, respectively,
into and out the remote insulin compartment where insu-
lin action is expressed. Si is an index of the influence of
plasma insulin to change the glucose effect per se on glu-
cose concentration. Thus, Si is equal to -p3/p2.
Sg was divided into its two components: the contribution
of hyperglycemia per se to tissue glucose utilization and
the effect of basal insulin on glucose uptake. The basal
insulin component of Sg is BIE and can be calculated as
the product of basal insulin Ib and Si: BIE = Ib × Si. Thus,
the contribution of non-insulin-dependent glucose
uptake (GEZI) to glucose uptake is the difference between
total Sg and the BIE: GEZI = Sg - (Ib × Si).
The sample size was calculated from clinical data on AIR
obtained in a control sample after FSIVGTT, with the 2-
sided hypothesis of a difference between diazepam and
placebo or clonazepam and placebo of at least 35%; the
study power was set at 90% and the significance threshold
at 5%. All the results are given as means ± standard error
(s.e. mean). Where necessary, 95% confidence intervals
on differences (95% CI) are given. The time courses of
mean cortisol concentrations were compared using
repeated measures ANOVA. Other kinetics data were inte-
grated in areas under the curves (AUC), calculated includ-
ing baseline by the trapezoidal rule using the Systat® 6.0
software for Windows®. AUC means were compared using
the nonparametric Friedman test for related data. Spear-
man correlations were performed between AIR and
diazepam or clonazepam concentrations. Post hoc and
subgroups analysis were performed where necessary using
the paired t-test for cortisol and the Wilcoxon rank-sum
test for other paired data. The Systat® 6.0 software for
Windows® was also used for the statistical analysis.
Results
Intravenous administration of 10 mg diazepam during 30
min yielded to plasma concentrations peaking at 370.1 ±
22.6 ngml-1 at time -15 min, just at the end of the infu-
sion. The concentrations rapidly decreased to 229.7 ± 12.6
ngml-1 at time 0, before glucose administration (Figure 1,
A). The mean concentrations of N-desmethyldiazepam
ranged between 3.2 ± 0.9 ngml-1 at min -15 and 9.1 ± 1.6
ngml-1 at min 180. Intravenous infusion of 1 mg clon-
azepam over 30 min led to a mean maximal concentra-
tion of 15.1 ± 2.0 ngml-1 at min -15 (Figure 1, B); the
mean concentrations at times 0 and 15 minutes were 6.6
± 0.5 and 4.9 ± 0.4 ngml-1, respectively.
Concerning the psychotropic effects of the drugs, the
pentobarbital-chlorpromazine-alcohol group (PCAG)
scores of the ARCI, which reflect sedation, were signifi-
cantly different with treatment (P < 0.001, Figure 2); a sig-
nificant increase was observed for diazepam (+363% vs
placebo, 95% CI: 214.0, 820.7, n = 15, P = 0.004) and
clonazepam (+593% vs placebo, 95% CI: 511.2, 1146.3, n
= 14, P = 0.001). The benzedrine group (BG) scores,
which explore stimulation, were also significantly differ-
ent with treatment (P < 0.017, Figure 2); a significant
decrease was observed for clonazepam (-153% vs placebo,
95% CI: -598.2, -170.3, n = 14, P = 0.004). Concerning
the other factors of the ARCI, the scores of the morphine-
benzedrine group (MBG), assessing euphoria, of the LSD
group, assessing dysphoric and psychotomimetic changes,
and of the amphetamine group, assessing amphetamine-
like effects were not significantly modified with treatment
(not shown). On the VAS, the self-rating of asthenia-
fatigue (factor 1) scores were also significantly modified
with treatment (P = 0.002), with a similar time-course as
the PCAG score of the ARCI (not shown); a significant
increase was observed for diazepam (+42.3% vs placebo,
95% CI: 899.1, 4501.6, n = 15, P = 0.015) and clon-
azepam (+70.3% vs placebo, 95% CI: 2402.2, 6516.4, n =
14, P = 0.002).
In addition, there was a significant difference (P = 0.028)
in the time course of plasma cortisol concentrationsBMC Clinical Pharmacology 2004, 4 http://www.biomedcentral.com/1472-6904/4/3
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Plasma concentrations after diazepam and clonazepam infusion Figure 1
Plasma concentrations after diazepam and clonazepam infusion. A Time course of plasma diazepam and N-desmethyldiazepam 
concentrations after 10 mg diazepam infusion (during 30 min from time -45 min to time -15 min) during FSIVGTT (0.5 g/kg glu-
cose load at time 0 min). ●  diazepam; ❍  N-desmethyldiazepam. B Time course of plasma clonazepam concentration after 1 mg 
clonazepam infusion (during 30 min from time -45 min to time -15 min) during FSIVGTT (0.5 g/kg glucose load at time 0 min). 
◆  clonazepam.BMC Clinical Pharmacology 2004, 4 http://www.biomedcentral.com/1472-6904/4/3
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between the different groups (Figure 3); a significant
reduction was observed at time 60 min for diazepam (-
33.3% vs  placebo, 95% CI: -130.4, -38.3, n = 15, P =
0.002) and clonazepam (-24.0% vs placebo, 95% CI: -
119.0, -2.6, n = 15, P = 0.042).
As shown in figure 4, the acute insulin responses (AIR)
were significantly and negatively correlated with the
plasma concentrations of clonazepam (r = -0.609, P <
0.05, n = 14) at time 0 minute, just before glucose injec-
tion. However, the mean AIR were not significantly differ-
ent between the benzodiazepine-treated subjects and the
controls (Table 1).
Overall, glucose tolerance, insulin sensitivity and glucose
effectiveness were not significantly different between the
benzodiazepine-treated subjects and the controls (Table
1). However, as shown in figure 5, a concentration-
dependent effect could be observed with clonazepam.
Indeed, in the subgroup of 7 subjects with plasma clon-
azepam concentrations at time 0 minute higher than 6.0
ngml-1 (median and lower limit of effective therapeutic
concentrations), each of these parameters was signifi-
cantly decreased as compared with placebo: -51.8% (95%
CI: -2.58, -0.37 × 10-2min-1, P = 0.028) for the coefficient
of glucose tolerance (Kg), -41.2% (95% CI: -3.04, -0.02 ×
10-4µUml-1min-1, P = 0.018) for insulin sensitivity (Si)
and -49.9% (95% CI: -3.07, -0.51 × 10-2min-1, P = 0.028)
for glucose effectiveness at basal insulin (Sg).
Time course of PCAG- and BG-scores of the ARCI after 10 mg diazepam, 1 mg clonazepam or placebo infusion (during 30 min  from time -45 min to time -15 min) during FSIVGTT (0.5 g/kg glucose load at time 0 min) Figure 2
Time course of PCAG- and BG-scores of the ARCI after 10 mg diazepam, 1 mg clonazepam or placebo infusion (during 30 min 
from time -45 min to time -15 min) during FSIVGTT (0.5 g/kg glucose load at time 0 min). ●  PCAG scores after diazepam infu-
sion; ◆  PCAG scores after clonazepam infusion; ▲  PCAG scores after placebo infusion; ❍  BG scores after diazepam infusion; 
 BG scores after clonazepam infusion;  BG scores after placebo infusion.BMC Clinical Pharmacology 2004, 4 http://www.biomedcentral.com/1472-6904/4/3
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Furthermore, the two components of Sg were significantly
decreased with clonazepam vs placebo in the subgroup of
subjects with the highest plasma clonazepam concentra-
tions at time 0 minute: -38.1% (95% CI: -0.18, -0.03 × 10-
2min-1, P = 0.018) for basal insulin effctiveness (BIE) and
-50.9% (95% CI: -2.97, -0.40 × 10-2min-1, P = 0.028) for
glucose effectiveness at zero insulin (GEZI).
Discussion
The present study investigated the effects of a single-dose
administration of different benzodiazepines on β-cell
function and insulin sensitivity in healthy volunteers.
Intravenous administration of 10 mg diazepam or 1 mg
clonazepam led to peak concentrations at the end of the
infusion within the standard effective plasma concentra-
tions of these drugs, namely 300–400 ngml-1  for
diazepam and 5–70 ngml-1 for clonazepam [14]. How-
ever, whereas the plasma levels of diazepam rapidely
decreased below the standard effective concentrations, the
mean concentrations of clonazepam further remained
around the lower limit of effective concentrations.
Both diazepam and clonazepam induced significant psy-
chological effects, as judged by the PCAG and BG scores of
the ARCI and the asthenia-fatigue factor of the VAS, which
is in accordance with previously reported data on the
subjective effects induced by benzodiazepines [15]. These
effects were still significant at time 70 minutes, ie approx-
imately one and a half hour after the end of the infusion,
although at that time, the PCAG and VAS factor 1 scores
were also increased in the placebo group. This latter
Time course of plasma cortisol after 10 mg diazepam, 1 mg clonazepam or placebo infusion (during 30 min from time -45 min  to time -15 min) during FSIVGTT (0.5 g/kg glucose load at time 0 min) Figure 3
Time course of plasma cortisol after 10 mg diazepam, 1 mg clonazepam or placebo infusion (during 30 min from time -45 min 
to time -15 min) during FSIVGTT (0.5 g/kg glucose load at time 0 min). ●  diazepam; ◆  clonazepam; ▲  placebo; * P < 0.05 for 
diazepam vs placebo and clonazepam vs placebo.BMC Clinical Pharmacology 2004, 4 http://www.biomedcentral.com/1472-6904/4/3
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observation may be the result of the hypoglycemia meas-
ured at that time (2.4 ± 0.1 mmoll-1) and resulting from
the insulin bolus, since acute hypoglycemia has been
reported to affect brain function and activation [16]. On
the other hand, the treatment by either benzodiazepine
also induced a significant biological effect on plasma cor-
tisol concentrations, which were decreased in the benzo-
diazepine-treated groups as compared with controls. This
result is in accordance with previous studies in the litera-
ture [17,18], although not all studies have reported that a
Correlation of acute insulin response (AIR), calculated from serum insulin concentrations obtained during the 10 first minutes  after glucose injection, with the plasma concentrations of clonazepam obtained at time 0 min, just before glucose injection (r' =  -0.609, P < 0.05, n = 14) Figure 4
Correlation of acute insulin response (AIR), calculated from serum insulin concentrations obtained during the 10 first minutes 
after glucose injection, with the plasma concentrations of clonazepam obtained at time 0 min, just before glucose injection (r' = 
-0.609, P < 0.05, n = 14).
Table 1: Values of the parameters of insulin secretion, glucose tolerance, insulin sensitivity and glucose effectiveness according to the 
different treatment-groups.
Treatment AIR (µUml-1)K g (× 10-2min-1)S i (× 10-4µUml-1min-1)S g (× 10-2min-1)
Diazepam 52.9 ± 13.7 2.27 ± 0.26 3.52 ± 0.52 2.98 ± 0.30
Clonazepam 51.2 ± 8.6 1.78 ± 0.37 3.70 ± 0.79 2.39 ± 0.48
Placebo 53.9 ± 10.7 2.65 ± 0.31 3.50 ± 0.47 3.42 ± 0.37BMC Clinical Pharmacology 2004, 4 http://www.biomedcentral.com/1472-6904/4/3
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Effects of clonazepam on glucose tolerance, insulin sensitivity and glucose effectiveness Figure 5
Effects of clonazepam on glucose tolerance, insulin sensitivity and glucose effectiveness. A Effect of clonazepam on glucose tol-
erance (Kg) according to plasma clonazepam concentration. White bars, controls; Striped bars, treated; * P < 0.05 vs placebo. B 
Effect of clonazepam on insulin sensitivity (Si) according to plasma clonazepam concentration. White bars, controls; Striped bars, 
treated; * P < 0.05 vs placebo. C Effect of clonazepam on glucose effectiveness at basal insulin (Sg) according to plasma clon-
azepam concentration.White bars, controls; Striped bars, treated; * P < 0.05 vs placebo.BMC Clinical Pharmacology 2004, 4 http://www.biomedcentral.com/1472-6904/4/3
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single dose of benzodiazepine affects cortisol secretion in
healthy volunteers [19]. This effect of benzodiazepines on
cortisol is in agreement with the inhibiting action of
gabaergic agonists on the corticotropin releasing hor-
mone secretion, as observed in vitro in rats [20]. It can also
be observed that there is a relative increase in plasma cor-
tisol concentrations following the lowest glucose concen-
trations (at time 70 minute), and that this cortisol
response to insulin-induced hypoglycemia is not affected
by either benzodiazepine, in accordance with some [21]
but not all previously reported data [22].
Considering the metabolic effects, the present study
shows that clonazepam is able to reduce the acute insulin
response to a glucose challenge in healthy volunteers, in a
concentration-dependent manner. This result is in accord-
ance with previously reported data showing that
Diazepam Binding Inhibitor (DBI), which is an endog-
enous ligand for both central and peripheral benzodi-
azepine receptors, dose-dependently inhibited glucose-
induced insulin secretion in vitro in rat isolated islets
[23,24]. In the same way, it supports previous observa-
tions that benzodiazepines or related compounds alter
glucose tolerance in vivo in the rat [25] or in patients [4].
Other experiments however have shown in vitro that drugs
acting specifically at peripheral benzodiazepine receptors
inhibit glucose-induced insulin secretion [5] by reducing
oxidative metabolism [26], whereas clonazepam, which
binds very weakly to peripheral sites [27], is ineffective
[5]. The peripheral-type receptor agonist, 4'-chlo-
rdiazepam, was also reported to increase glycaemia after
intraperitoneal administration in the mice [28]. These dis-
crepant data concerning clonazepam may be due to spe-
cies variations or the result of an indirect central effect of
the drug in our study. At the concentrations obtained with
the single dose administered, there was no overall effect of
clonazepam on the acute insulin response according to
the different groups. Diazepam was ineffective as well,
which may be the result of too low plasma concentrations
over time. It is noteworthy to observe that both drugs
however have significant psychotropic effects as well as
effects on cortisol, even after 75 min after the end of the
infusion, suggesting differential potencies relative to these
effects.
On the other hand, this study shows for the first time that
a benzodiazepine can reduce both insulin sensitivity (Si)
and non-insulin-mediated glucose disposal (Sg and its
components), provided that its concentration is above the
admitted therapeutic threshold. Apart from the peak
concentrations, this was especially the case for clon-
azepam but not for diazepam. There is no clear
explanation for that observation. However, since insulin
sensitivity and non-insulin mediated glucose disposal
have been shown to increase even shortly after muscular
activity [13], it can be tentatively speculated that the well-
known muscle relaxant action of the benzodiazepine may
alter insulin sensitivity and glucose disposal.
Conclusions
Even if clinical metabolic events related to benzodi-
azepines are uncommon, the results of the present study
on both insulin secretion and insulin action prompt to
suggest that, on the long term, these drugs may be a poten-
tial risk factor for glycemic dysregulation.
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